TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Fedewa, S. A. AU - Ahnen, D. J. AU - Meester, R. G. S. AU - Barzi, A. PY - 2017 DA - 2017// TI - Colorectal cancer statistics, 2017 JO - CA Cancer J Clin VL - 67 UR - https://doi.org/10.3322/caac.21395 DO - 10.3322/caac.21395 ID - Siegel2017 ER - TY - JOUR AU - Goldman, J. M. AU - Melo, J. V. PY - 2001 DA - 2001// TI - Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia JO - N Engl J Med VL - 344 UR - https://doi.org/10.1056/NEJM200104053441409 DO - 10.1056/NEJM200104053441409 ID - Goldman2001 ER - TY - JOUR AU - Tokarski, J. S. AU - Newitt, J. A. AU - Chang, C. Y. AU - Cheng, J. D. AU - Wittekind, M. AU - Kiefer, S. E. PY - 2006 DA - 2006// TI - The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against Imatinib-resistant ABL mutants JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-05-4187 DO - 10.1158/0008-5472.CAN-05-4187 ID - Tokarski2006 ER - TY - JOUR AU - Wallace, E. AU - Lyndon, W. AU - Chumley, P. AU - Jaimes, E. A. AU - Fatima, H. PY - 2013 DA - 2013// TI - Dasatinib-induced nephrotic-range proteinuria JO - Am J Kidney Dis VL - 61 UR - https://doi.org/10.1053/j.ajkd.2013.01.022 DO - 10.1053/j.ajkd.2013.01.022 ID - Wallace2013 ER - TY - JOUR AU - Hirano, T. AU - Hashimoto, M. AU - Korogi, Y. AU - Tsuji, T. AU - Miyanaka, K. AU - Yamasaki, H. PY - 2016 DA - 2016// TI - Dasatinib-induced nephrotic syndrome JO - Leuk Lymphoma VL - 57 UR - https://doi.org/10.3109/10428194.2015.1075020 DO - 10.3109/10428194.2015.1075020 ID - Hirano2016 ER - TY - STD TI - Ruebner RL, Copelovitch L, Evageliou NF, Denburg MR, Belasco JB, Kaplan BS. Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature. Pediatr Nephrol 2014;29:863–869. ID - ref6 ER - TY - JOUR AU - Lim, Y. T. AU - Kim, Y. J. AU - Park, Y. H. AU - Hah, J. O. AU - Lee, J. M. PY - 2016 DA - 2016// TI - A case of dasatinib-induced nephrotic syndrome in a child with Philadelphia chromosome positive acute lymphoblastic leukemia JO - Yonsei Med J VL - 57 UR - https://doi.org/10.3349/ymj.2016.57.2.532 DO - 10.3349/ymj.2016.57.2.532 ID - Lim2016 ER - TY - JOUR AU - Luca, M. L. AU - Carmosino, I. AU - Stefanizzi, C. AU - Campanelli, M. AU - Angelis, F. AU - Cesini, L. PY - 2016 DA - 2016// TI - Nephrotic proteinuria developed under dasatinib treatment in a patient with chronic myeloid leukemia: a case report and review of the literature JO - Ann Hematol Oncol VL - 3 ID - Luca2016 ER - TY - JOUR AU - Takahashi, D. AU - Nagahama, K. AU - Tsuura, Y. AU - Tanaka, H. AU - Tamura, T. PY - 2012 DA - 2012// TI - Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction JO - Clin Exp Nephrol VL - 16 UR - https://doi.org/10.1007/s10157-011-0543-9 DO - 10.1007/s10157-011-0543-9 ID - Takahashi2012 ER - TY - JOUR AU - Quintyne, K. I. AU - Neenan, T. AU - Casserly, L. AU - Gupta, R. PY - 2014 DA - 2014// TI - Uncommon side effect with a commonly used targeted agent: sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma JO - BMJ Case Rep VL - 28 ID - Quintyne2014 ER - TY - JOUR AU - Demetri, G. D. AU - Lo Russo, P. AU - MacPherson, I. R. AU - Wang, D. AU - Morgan, J. A. AU - Brunton, V. G. PY - 2009 DA - 2009// TI - Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-09-0224 DO - 10.1158/1078-0432.CCR-09-0224 ID - Demetri2009 ER - TY - JOUR AU - Montero, J. C. AU - Seoane, S. AU - Ocaña, A. AU - Pandiella, A. PY - 2011 DA - 2011// TI - Inhibition of Src family kinases and receptor tyrosine kinases by Dasatinib: possible combinations in solid tumors JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-10-2616 DO - 10.1158/1078-0432.CCR-10-2616 ID - Montero2011 ER - TY - JOUR AU - Liang, W. AU - Kujawski, M. AU - Wu, J. AU - Lu, J. AU - Herrmann, A. AU - Loera, S. PY - 2010 DA - 2010// TI - Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment JO - Clin Cancer Res VL - 16 UR - https://doi.org/10.1158/1078-0432.CCR-09-1486 DO - 10.1158/1078-0432.CCR-09-1486 ID - Liang2010 ER - TY - JOUR AU - Advani, A. PY - 2014 DA - 2014// TI - Vascular endothelial growth factor and the kidney: something of the marvellous JO - Curr Opin Nephrol Hypertens VL - 23 UR - https://doi.org/10.1097/01.mnh.0000437329.41546.a9 DO - 10.1097/01.mnh.0000437329.41546.a9 ID - Advani2014 ER - TY - JOUR AU - Pfister, F. AU - Amann, K. AU - Daniel, C. AU - Klewer, M. AU - Büttner, A. AU - Büttner-Herold, M. PY - 2018 DA - 2018// TI - Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy JO - Histopathology. VL - 73 UR - https://doi.org/10.1111/his.13716 DO - 10.1111/his.13716 ID - Pfister2018 ER - TY - JOUR AU - Weisberg, E. AU - Manley, P. W. AU - Breitenstein, W. AU - Bruggen, J. AU - Cowan-Jacob, S. W. AU - Ray, A. PY - 2005 DA - 2005// TI - Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl JO - Cancer Cell VL - 7 UR - https://doi.org/10.1016/j.ccr.2005.01.007 DO - 10.1016/j.ccr.2005.01.007 ID - Weisberg2005 ER - TY - JOUR AU - Kim, I. K. AU - Rhee, C. K. AU - Yeo, C. D. AU - Kang, H. H. AU - Lee, D. G. AU - Lee, S. H. PY - 2013 DA - 2013// TI - Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery JO - Crit Care VL - 20 UR - https://doi.org/10.1186/cc12786 DO - 10.1186/cc12786 ID - Kim2013 ER - TY - JOUR AU - Wiggins, R. C. PY - 2007 DA - 2007// TI - The spectrum of podocytopathies: a unifying view of glomerular diseases JO - Kidney Int VL - 71 UR - https://doi.org/10.1038/sj.ki.5002222 DO - 10.1038/sj.ki.5002222 ID - Wiggins2007 ER - TY - JOUR AU - Sato, Y. AU - Wharram, B. L. AU - Lee, S. K. AU - Wickman, L. AU - Goyal, M. AU - Venkatareddy, M. PY - 2009 DA - 2009// TI - Urine podocyte mRNAs mark progression of renal disease JO - J Am Soc Nephrol VL - 20 UR - https://doi.org/10.1681/ASN.2007121328 DO - 10.1681/ASN.2007121328 ID - Sato2009 ER - TY - JOUR AU - Rosenstock, J. L. AU - Markowitz, G. S. AU - Valeri, A. M. AU - Sacchi, G. AU - Appel, G. B. AU - D'Agati, V. D. PY - 2003 DA - 2003// TI - Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features JO - Kidney Int VL - 63 UR - https://doi.org/10.1046/j.1523-1755.2003.00853.x DO - 10.1046/j.1523-1755.2003.00853.x ID - Rosenstock2003 ER - TY - JOUR AU - Fogo, A. AU - Qureshi, N. AU - Horn, R. G. PY - 1993 DA - 1993// TI - Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy JO - Am J Kidney Dis VL - 22 UR - https://doi.org/10.1016/S0272-6386(12)70138-5 DO - 10.1016/S0272-6386(12)70138-5 ID - Fogo1993 ER - TY - JOUR AU - Nasr, S. H. AU - Valeri, A. M. AU - Cornell, L. D. AU - Fidler, M. E. AU - Sethi, S. AU - Leung, N. PY - 2011 DA - 2011// TI - Fibrillary glomerulonephritis: a report of 66 cases from a single institution JO - Clin J Am Soc Nephrol VL - 6 UR - https://doi.org/10.2215/CJN.08300910 DO - 10.2215/CJN.08300910 ID - Nasr2011 ER - TY - JOUR AU - Nasr, S. H. AU - Vrana, J. A. AU - Dasari, S. AU - Bridoux, F. AU - Fidler, M. E. AU - Kaaki, S. PY - 2018 DA - 2018// TI - DNAJB9 is a specific Immunohistochemical marker for fibrillary glomerulonephritis JO - Kidney Int Rep VL - 3 UR - https://doi.org/10.1016/j.ekir.2017.07.017 DO - 10.1016/j.ekir.2017.07.017 ID - Nasr2018 ER -